Amifostine otoprotection to cisplatin ototoxycity: A guinea pig study using otoacoustic emissions: Distortion products (DPOEA) and scanning microscopy;Otoproteção da amifostina aos efeitos otótoxicos da cisplatina: Estudo em cobaias albinas por emissões otoacústicas produtos de distorção e microscopia eletrônica de varredura

Revista Brasileira de Otorrinolaringologia

Volumn 71, Issue 3, 2005, Pages 268-273

  Hyppolito, Miguel Angelo ^a   De Oliveira, José Antonio A ^a   Miranda Lessa, Ricardo ^a   Rossato, Maria ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Técnico de Laboratório

Author keywords

Amifostine; Cisplatin; Otoprotective agents

Indexed keywords

AMIFOSTINE; CISPLATIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISTORTION PRODUCT OTOACOUSTIC EMISSION; DRUG EFFECT; GUINEA PIG; HAIR CELL; NONHUMAN; OTOSCOPY; OTOTOXICITY; PROTECTION; SCANNING ELECTRON MICROSCOPY;

EID: 23844527954     PISSN: 00347299     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0034-72992005000300002     Document Type: Article

References (26)

1. Gandara DR, Perez EA, Wiebe V, De Gregorio MW. Cisplatin Chemoprotection and Rescue: pharmacologic modulation of toxicity. Sem Oncology 1991; 18: 49-55.
2. Fiel IJ, Meyer D, Percia CP, Wolfe VI. Effects of cisdiamminedichoroplatinun (NSC - 119875) on hearing function in man. Cancer Chemother Rep 1974; 58: 871-5.
3. Drescheler WA, Van Der Hulst RJ, Tange RA, Urbanus NA. Role of high-frequency audiometry in the early detection of ototoxicity. II - clinical aspects. Audiology 1989; 28(4): 211-20.
4. McAlpine D, Johnstone BM. The ototoxic mechanism of cisplatin. Hear Res 1990; 47: 191-203.
5. Schewetzer VG. Cisplatin induced ototoxicity: the effect of pigmentation and inhibitory agents. The Laryngoscope 1993; 103 Suppl 59.
6. Ravi R, Somani SM, Rybak LP. Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacology & Toxicology 1995; 76: 386-94.
7. Glover D, Glick J, Weiter C. Phase I/II Trials of WR-2721 and Cisplatin. Int. J. Radiât Oncol Biol Phys 1986; 12: 1509-12.
8. Kalaycioglu M, Bukowski R. Clinical Status of the new chemoprotective agent amifostine. Oncology 1994; 8: 15-23.
9. Glover D, Glick J, Weiter C. WR-2721 and High-dose Cisplatin: an active Combination in the Treatment of Metastatic Melanoma. J Clin Oncol 1987; 5: 574-8.
10. Yohas JM & Culo F. Selective Inhibition of the Nephrotoxicity of Cisdichlorodiammineplatinun (II) by WR-2721 Without Altering its Antitumor Properties. Cancer Treat Rep 1980; 64: 57-64.
11. Mollman JE, Glover DJ, Hogen WM. Cisplatin Neuropathy: risk factors prognosis and protection by WR-2721. Cancer 1988; 61: 2192-5.
12. Rubin JS, Waler S, Beitter JJ, Haynes H, Razenblit A, Mcgill F, Goldeberg G, Runowicz C. Audiological findings in a phase I protocol investigating the effect of WR-2721 high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma. J Laryngol Otol 1995; 109: 744-7.
13. Foster Nora JA & Siden R. Amifostine for Protection From Antineoplastic Drug Toxicity. Am J Health Syst Pharm 1997; (54) 787-800.
14. Ramath N, Lorusso P, Simon M. Phase II evaluation of cisplatin and WR-2721 of refractory metastatic breast cancer. Am J Clin Oncol 1997; 20: 368-72.
15. Church MW, Kaltenbach JA, Blakley BW, Burgio DL. The Comparative Effects of Sodium Thiosulfate Diethyldithiocarbamate Fosfomycin and WR-2721 on Ameliorating Cisplatin - induced ototoxicity. Hear Res 1995; 86 (1-2): 195-203.
16. Kaltenbach JA, Church MW, Blakley BW, McCaslin DL, Burgio DL. Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster. Otolaryngol Head Neck Surg 1997; 117(5): 493-500.
17. Jero J, Coling DE, Lalwani AK. The use of Preyer's reflex in evaluation of hearing in mice. Acta Otolaryngol Jul 2001; 121(5): 585-9.
18. Preyer W. Die Seele des Kindes. Leipzig: Grieben - Verlag; 1882.
19. He NJ, Schmiedt RA. Fine structure of the 2F1-F2 acoustic distortion product: changes with primary level. J Acoust Soc Am 1993; 94(5): 2659-69.
20. Rasmussen AN, Popelka GR. Osterhammel PA, Nielsen LH. Clinical significance of relative probe tone levels on distortion products otoacoustic emissions. Scand Audiol 1993; 22(4): 223-9.
21. Lopes Filho O, Carlos R, Redondo MC. Produtos de distorção das emissões otoacústicas. Rev Brasileira de Otorrinolaringologia 1995; 61(6): 485-94.
22. Saito T, Aran J.M. Comparative ototoxicity of cisplatin during acute and chronic treatment. ORL J Otorhinolaryngol Relat Spec 1994; 56(6): 315-20.
23. Cardinaal RM, Groot JCMJ, Huizing EH, Veldman JE, Smoorenburg G.F.Dose-dependent effect of 8-day cisplatin administration upon the morphology of the albino guinea pig cochlea. Hearing Res 2000; 144: 135-46.
24. Demarco RC. Uso da gentamicina intra-timpânica para induzir ablação vestibular unilateral em cobaias. Tese de Dissertação de Mestrado FMRP-USP; 2001.
25. Oliveira JAAO, Canedo DM, Rossato M. Autodefesa contra a ototoxicidade de antibióticos aminoglicosídeos. Rev Brasileira de Otorrinolaringologia 2002; 68(1): 7-13.
26. Vincent M, Bramwell V, Moran LA, Anderson D. Use of aminfostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer. Toronto(ON): Cancer Care Ontario (OCO). Practice Guideline 2003; 12-6.